Almoosa Health Company (4018.SR) — Financial statements
Income statement, balance sheet, and cash flow for Almoosa Health Company — annual and quarterly history with growth and margin analysis.
| Metric (SAR Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 1,416↑17.8% | 1,202↑22.8% | 979↑20.0% | 816↑16.3% | 702 | |
| Cost of Revenue | 968↑15.1% | 841↑19.8% | 701↑16.0% | 605↑21.5% | 498 | |
| Gross Profit | 449↑24.0% | 362↑30.3% | 278↑31.3% | 211↑3.8% | 204 | |
| Operating Expenses | ||||||
| R&D Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| General & Administrative Expenses | 0.00↓100.0% | 170 | 0.00 | 0.00 | 0.00 | |
| Selling & Marketing Expenses | 0.00↓100.0% | 25 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 246↑28.8% | 191↑18.5% | 161↑3.2% | 156↑13.8% | 137 | |
| Other Expenses | 0.00↑100.0% | -9 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 246↑35.4% | 181↑11.9% | 162↑4.0% | 156↑13.8% | 137 | |
| Total Costs & Expenses | 1,213↑17.6% | 1,032↑219.5% | -863↓13.5% | -760↓19.8% | -635 | |
| Operating Results | ||||||
| Operating Income | 203↑19.2% | 170↑47.5% | 116↑107.9% | 56↓16.8% | 67 | |
| Depreciation & Amortization | 0.00↓100.0% | 83↑26.1% | 66↑13.4% | 58↑104.5% | 28 | |
| EBITDA | 203↓24.0% | 267↑37.8% | 194↑49.8% | 129↑24.8% | 104 | |
| EBIT | 203↑10.4% | 184↑43.8% | 128↑79.6% | 71↓5.4% | 75 | |
| Interest & Other Income | ||||||
| Net Interest Income | -15↑81.3% | -82↓215.5% | -26↓67.0% | -16↓371.5% | -3 | |
| Interest Income | 9 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Interest Expense | 24↓70.8% | 82↑215.5% | 26↑67.0% | 16↑371.5% | 3 | |
| Non-Operating Income | 0.00↑100.0% | -14↓9.9% | -12↑21.0% | -16↓84.9% | -8 | |
| Other Income / Expenses | 2↑102.2% | -68↓391.2% | -14↓513141.0% | -0.00↓100.1% | 5 | |
| Income Before Tax | 205↑98.9% | 103↑1.1% | 102↑83.2% | 56↓22.7% | 72 | |
| Income Tax Expense | 4↓50.2% | 8↑132.1% | 4↓20.1% | 5↓52.0% | 9 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | 200↑112.2% | 94↓3.8% | 98↑92.4% | 51↓18.3% | 62 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | 200↑112.2% | 94↓3.8% | 98↑92.4% | 51↓18.3% | 62 | |
| Bottom-Line Net Income | 200↑112.2% | 94↓3.8% | 98↑92.4% | 51↓18.3% | 62 | |
| EPS (Basic) | 4.54↑113.1% | 2.13↓4.1% | 2.22↑93.0% | 1.15↓18.4% | 1.41 | |
| EPS (Diluted) | 4.54↑113.1% | 2.13↓4.1% | 2.22↑93.0% | 1.15↓18.4% | 1.41 | |
| Weighted Average Shares | 44↓0.4% | 44↑0.0% | 44↑0.0% | 44↑0.0% | 44 | |
| Weighted Average Diluted Shares | 44↓0.4% | 44↑0.0% | 44↑0.0% | 44↑0.0% | 44 | |
* All figures in Millions of SAR, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.